

Annabelle Mahar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8267454/publications.pdf>

Version: 2024-02-01

31
papers

958
citations

687363

13
h-index

454955

30
g-index

31
all docs

31
docs citations

31
times ranked

1743
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 171-181.	10.7	253
2	Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis. <i>DMM Disease Models and Mechanisms</i> , 2017, 10, 1301-1312.	2.4	110
3	Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4569-4577.	7.0	96
4	Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry. <i>Respirology</i> , 2017, 22, 950-956.	2.3	85
5	Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. <i>BMC Pulmonary Medicine</i> , 2018, 18, 19.	2.0	58
6	An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2018, 7, 153.	2.4	47
7	The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. <i>Respirology</i> , 2017, 22, 1459-1472.	2.3	41
8	Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2017, 50, 1700168.	6.7	32
9	Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma. <i>Journal of Hematology and Oncology</i> , 2016, 9, 48.	17.0	28
10	Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes. <i>PLoS ONE</i> , 2020, 15, e0222551.	2.5	26
11	The tumor suppressor Hic1 maintains chromosomal stability independent of Tp53. <i>Oncogene</i> , 2018, 37, 1939-1948.	5.9	18
12	Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer: correlation with clinicopathological features and tumour mutation status. <i>Journal of Clinical Pathology</i> , 2021, 74, 123-128.	2.0	16
13	Histopathologic Assessment of Suspected Idiopathic Pulmonary Fibrosis: Where We Are and Where We Need to Go. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1477-1489.	2.5	14
14	Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary. <i>Medical Journal of Australia</i> , 2018, 208, 82-88.	1.7	13
15	Atypical Ewing sarcoma breakpoint region 1 fluorescence <i>in situ</i> hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases. <i>Histopathology</i> , 2016, 69, 1000-1011.	2.9	12
16	Diffuse malignant mesothelioma and synchronous lung cancer: A clinicopathological study of 18 cases. <i>Lung Cancer</i> , 2016, 95, 1-7.	2.0	12
17	FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 38-47.	1.1	11
18	Prolonged Disease Control on Nivolumab for Primary Pulmonary NUT Carcinoma. <i>Clinical Lung Cancer</i> , 2021, 22, e665-e667.	2.6	11

#	ARTICLE	IF	CITATIONS
19	Updates in the molecular pathology of non-small cell lung cancer. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 54-61.	1.5	10
20	GLI activated epithelioid cell tumour: report of a case and proposed new terminology. <i>Pathology</i> , 2021, 53, 267-270.	0.6	9
21	NR4A3 Immunohistochemistry Lacks Sensitivity for the Diagnosis of Extraskeletal Myxoid Chondrosarcoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1726-1728.	3.7	8
22	Genome wide methylation profiling of selected matched soft tissue sarcomas identifies methylation changes in metastatic and recurrent disease. <i>Scientific Reports</i> , 2021, 11, 667.	3.3	8
23	PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma. <i>Cancer Reports</i> , 2021, 4, e1327.	1.4	8
24	Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100075.	1.1	8
25	Clinical Utility of In Situ Hybridization Assays in Head and Neck Neoplasms. <i>Head and Neck Pathology</i> , 2019, 13, 397-414.	2.6	5
26	ROS1 rearrangements in lung adenocarcinomas are defined by diffuse strong immunohistochemical expression of ROS1. <i>Pathology</i> , 2022, 54, 399-403.	0.6	5
27	NKX3.1 immunohistochemistry is highly specific for the diagnosis of mesenchymal chondrosarcomas: experience in the Australian population. <i>Pathology</i> , 2021, 53, 705-712.	0.6	4
28	Pigmented Paget's disease of the nipple mistaken for melanoma in situ : a diagnostic pitfall for the unwary. <i>Pathology</i> , 2018, 50, 364-367.	0.6	3
29	Mammary-type myofibroblastoma in the head and neck region. <i>Pathology</i> , 2019, 51, 544-547.	0.6	3
30	Micronodular thymoma with lymphoid stroma: a clinicopathological study of five cases. <i>Pathology</i> , 2021, 53, 930-933.	0.6	2
31	Cutaneous clear cell sarcoma with an epidermal component mimicking melanoma. <i>Pathology</i> , 2022, 54, 369-371.	0.6	2